GVAX is a cancer vaccine composed of whole tumor cells genetically modified to secrete the immune stimulatory cytokine, granulocyte-macrophage colony-stimulating factor (GM-CSF), and then irradiated to prevent further cell division.

GVAX is a granulocyte-macrophage colony-stimulating factor (GM-CSF) gene-transfected tumor cell vaccine. Original work with GM-CSF as a recombinant DNA protein (Leukine) involved proliferative stimulation of macrophages and neutrophils for the purpose of reducing hematopoietic toxicity related to do …

Colon GVAX is an allogeneic, whole‐cell, granulocyte‐macrophage colony‐stimulating factor‐secreting cellular immunotherapy that induces T‐cell immunity against tumor‐associated antigens and has previously been studied in combination with low‐dose cyclophosphamide (Cy) to inhibit regulatory T cells.

Aug 2, 2021 · Vaccination using irradiated, GM-CSF producing tumor cells (GVAX) consistently induced antitumor immunity across several experimental tumor models.

GVAX® is an investigational allogeneic cancer vaccine platform based on the local production of granulocyte-macrophage colony stimulating factor (GM-CSF) at the vaccine site to generate a systemic tumor-specific immune response.

May 31, 2023 · GVAX is an allogenic, whole cell, GM-CSF-secreting vaccine that activates T-cell immunity against tumor-associated antigens. Prior work has shown that GVAX in combination with low-dose cyclophosphamide (Cy) can inhibit T-regulatory cells and induce both PD-L1 expression and the formation of tertiary lymphoid aggregates.

Feb 8, 2019 · The GVAX vaccines are composed of whole tumor cells genetically modified to secrete the immune stimulatory cytokine, granulocyte-macrophage colony-stimulating factor (GM-CSF), a potent ...

Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting allogeneic pancreatic tumor cell (GVAX) immunotherapy consists of two irradiated human allogeneic pancreatic tumor cell lines modified to secrete GM-CSF, a cytokine that induces the maturation of dendritic cells.

Prostate cancer is among the diseases where a large amount of promising data has been accumulating regarding several distinct active immunotherapies. Here the authors review one of the therapies, known as GVAX, which is among the furthest along in clinical evaluation.

Jul 21, 2014 · GVAX is made from irradiated pancreatic cell lines that secrete GM-CSF. Low-dose cyclophosphamide is administered prior to GVAX, to prevent regulatory T cells from inhibiting the...